All In Biotech

NDA 021225 · Bayer Hlthcare

Mirena

Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System

Last checked: Nov 20, 2026Latest source record: Aug 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Dec 6, 2000

Approved uses

6

Original approval plus efficacy supplements

Registered trials

354

70 Phase 3, 26 recruiting

FAERS reports

137,670

57,435 serious, 251 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2025.

Mirena is a progestin-containing intrauterine system (IUS) indicated for: • Prevention of pregnancy for up to 8 years ( 1.1 ) • Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception for up to 5 years. ( 1.2 ) 1.1 Contraception Mirena is indicated for prevention of pregnancy for up to 8 years; replace after the end of the eighth year. 1.2 Heavy Menstrual Bleeding Mirena is indicated for the treatment of heavy menstrual bleeding for up to 5 years in women who choose to use intrauterine contraception as their method of contraception; replace after the end of the fifth year if continued treatment of heavy menstrual bleeding is needed.

Mechanism: The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Mirena has not been conclusively demonstrated. Studies of Mirena and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium .

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MIRENA · LEVONORGESTREL 52MG · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.

All 354 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device expulsion37,023
  • device dislocation17,421
  • genital haemorrhage10,061
  • abdominal pain lower7,609
  • pain6,843
  • vaginal haemorrhage6,790
  • uterine perforation6,746
  • abdominal pain6,704
  • procedural pain6,053
  • intra-uterine contraceptive device expelled5,573
  • pregnancy with contraceptive device4,955
  • complication of device insertion4,811

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004313
2005505
2006655
2007867
200810,604
20098,233
20103,123
201116,021
201210,282
20138,743
20148,338
20157,366
20166,713
20178,989
20187,599
20196,146
20206,285
20215,461
20224,736
20234,652
20244,847
20254,178
20263,014

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mirena (Levonorgestrel)

2024 spending

$758K

Beneficiaries

660

664 claims

Per beneficiary

$1,148

$1,141.29 per unit

View as table
YearSpending
2020$585,899
2021$661,026
2022$697,253
2023$777,252
2024$757,819

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,419 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.